Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654186 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
A Phase 2 study, sponsored by Oncology Specialists, S.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00654186 is a Phase 2 study that has completed, run by Oncology Specialists, S.C.. The registered enrollment target is 32 participants.
The verdict
NCT00654186, a Phase 2 study, has completed, sponsored by Oncology Specialists, S.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve. Patients will receive Revlimid® 25 mg daily on Days 1-21 followed by 7 days of rest repeated every 28 days. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion.
Interventions
- DRUG Revlimid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654186
The ClinicalTrials.gov registry entry for NCT00654186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncology Specialists, S.C., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Revlimid is the first listed.
NCT00654186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654186 about?
NCT00654186 is a clinical study titled "Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients". This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve. Patients will receive Revlimid® 25 mg daily on Days 1-21 followed by 7 days of rest repeated every 28 days. Treatment continues until disease progression, patient's w...
What is the current status of trial NCT00654186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2008-02. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00654186?
The interventions under investigation include: Revlimid (DRUG).
Who is sponsoring clinical trial NCT00654186?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.